# Nutex Health Inc. (NUTX)

Informational only - not investment advice.

CIK: 0001479681
SIC: 7389 Services-Business Services, NEC
SIC breadcrumb: [Services](/division/I/) > [Business Services](/major-group/73/) > [SIC 7389 Services-Business Services, NEC](/industry/7389/)
Latest 10-K filed: 2026-03-05
SEC page: https://www.sec.gov/edgar/browse/?CIK=1479681
Filing source: https://www.sec.gov/Archives/edgar/data/1479681/000162828026015168/nutx-20251231.htm

## At a glance

FY2025 · period end 2025-12-31 · filed 2026-03-05 · accession 0001628280-26-015168 · source: https://data.sec.gov/api/xbrl/companyfacts/CIK0001479681.json

| Metric | Value | FY | Provenance |
| --- | ---: | ---: | --- |
| Revenue | 875,257,000 USD | 2025 | verified |
| Net income | 70,789,000 USD | 2025 | verified |
| Assets | 918,525,000 USD | 2025 | verified |
| Free cash flow | 245,599,000 USD | 2025 | computed |
| Net margin | 8.09% | 2025 | computed |
| Operating margin | 31.49% | 2025 | computed |
| Revenue YoY | +82.36% | 2025 | computed |
| ROE | 21.49% | 2025 | computed |

Computed values are grepcent-computed from the verified facts above and may differ from ratios the company itself reports. Free cash flow = operating cash flow − capital expenditures. Net margin = net income ÷ revenue. Operating margin = operating income ÷ revenue. Revenue YoY = FY2025 revenue ÷ FY2024 revenue − 1 (consecutive fiscal years only). ROE = net income ÷ period-end stockholders' equity.

No market price, no rating, no forecast on this site. Not investment advice.

### Peer percentile fingerprint

| Ratio | NUTX | Peer median | Percentile | N |
| --- | ---: | ---: | ---: | ---: |
| Net margin | 8.1% | 5.8% | 59 | 59 |
| Operating margin | 31.5% | 9.2% | 89 | 56 |
| Revenue growth | 82.4% | 8.4% | 100 | 58 |
| FCF margin | 28.1% | 14.2% | 84 | 58 |
| ROE | 21.5% | 8.7% | 73 | 52 |
| ROA | 7.7% | 2.9% | 76 | 59 |
| Liabilities / equity | 1.50 | 1.52 | 47 | 54 |
| Current ratio | 3.41 | 1.34 | 95 | 57 |

Percentile = share of the N covered peers reporting that ratio whose value is lower (ties counted half); computed among grepcent-covered companies in SIC industry 7389 Services-Business Services, NEC, not the whole market. A higher percentile means a higher value of the ratio, not a better company. Ratios with fewer than 8 reporting peers are omitted. Latest reported values per company; fiscal periods may differ. Descriptive arithmetic - not a score, rating, or ranking.

## Selected Fundamentals
| Metric | Value | Unit | FY | Filed |
| --- | ---: | --- | ---: | --- |
| Revenue | 875257000 | USD | 2025 | 2026-03-05 |
| Net income | 70789000 | USD | 2025 | 2026-03-05 |
| Assets | 918525000 | USD | 2025 | 2026-03-05 |

## Financials

Annual standardized facts from SEC companyfacts as of latest extracted filing date 2026-03-05. Source: https://data.sec.gov/api/xbrl/companyfacts/CIK0001479681.json. Derived margins, ratios, and free cash flow are computed from the extracted annual SEC facts.

| Metric | 2014 | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
| --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Revenue |  |  |  |  | 1,366,996 | 1,366,419 | 274,029,061 | 331,531,311 | 219,294,306 | 247,646,000 | 479,949,000 | 875,257,000 |
| Net income |  |  | -7,432,241 | 582,062 | -950,129 | -7,116,520 | 105,969,885 | 132,593,328 | -424,780,446 | -45,787,000 | 52,097,000 | 70,789,000 |
| Operating income |  |  | -448,595 | -5,692,920 | -840,398 | -6,897,848 | 153,173,887 | 170,264,898 | -406,599,154 | -31,774,000 | 130,698,000 | 275,625,000 |
| Gross profit |  |  | 0.00 | -7,315 | 859,356 | 535,976 | 157,606,159 | 179,280,958 | 15,421,738 | 34,774,000 | 196,261,000 | 444,281,000 |
| Diluted EPS |  |  |  |  |  |  | 0.18 | 0.22 | -100.36 | -10.39 | 9.69 | 10.48 |
| Operating cash flow |  |  | -274,223 | -714,623 | -480,049 | -4,040,578 | 86,671,757 | 173,432,486 | 50,607,108 | 1,257,000 | 23,153,000 | 248,125,000 |
| Capital expenditures | 2,026 | 1,797 |  |  | 0.00 | 84,002 | 61,188,768 | 36,926,591 | 14,632,414 | 9,497,000 | 2,304,000 | 2,526,000 |
| Share buybacks |  |  |  |  |  |  |  |  |  | 0.00 | 0.00 | 5,000,000 |
| Assets |  |  | 510,835 | 3,328,755 | 449,428 | 6,692,504 | 169,857 | 394,650,043 | 431,751,985 | 398,245,497 | 655,320,000 | 918,525,000 |
| Liabilities |  | 6,076,680 | 6,380,260 |  | 1,946,781 | 4,834,071 | 1,303,652 | 203,069,033 | 311,424,585 | 319,139,391 | 466,787,000 | 495,088,000 |
| Stockholders' equity |  |  | -5,869,425 | -997,224 | -1,497,353 | 1,858,433 | -1,133,795 | 114,651,306 | 95,862,701 | 61,453,190 | 132,439,000 | 329,447,000 |
| Cash and cash equivalents |  |  | 10,522 | 9,449 | 119,267 | 1,065,434 | 26,931 | 36,118,284 | 34,255,000 | 22,002,000 | 40,640,000 | 185,574,000 |
| Free cash flow |  |  |  |  | -480,049 | -4,124,580 | 25,482,989 | 136,505,895 | 35,974,694 | -8,240,000 | 20,849,000 | 245,599,000 |

### Ratios

ROE and ROA use period-end equity/assets. Liabilities / equity uses total liabilities divided by stockholders' equity. Current ratio uses current assets divided by current liabilities when both are reported.

| Metric | 2014 | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
| --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Net margin |  |  |  |  | -69.50% |  | 38.67% | 39.99% |  | -18.49% | 10.85% | 8.09% |
| Operating margin |  |  |  |  | -61.48% |  | 55.90% | 51.36% |  | -12.83% | 27.23% | 31.49% |
| Return on equity |  |  |  |  |  | -382.93% |  | 115.65% | -443.11% | -74.51% | 39.34% | 21.49% |
| Return on assets |  |  |  | 17.49% |  | -106.34% |  | 33.60% | -98.39% | -11.50% | 7.95% | 7.71% |
| Liabilities / equity |  |  |  |  |  | 2.60 |  | 1.77 | 3.25 | 5.19 | 3.52 | 1.50 |
| Current ratio |  |  | 0.08 | 0.06 | 0.29 | 0.27 | 0.14 | 4.09 | 1.79 | 1.56 | 1.90 | 3.41 |

## As-reported value updates

23 tracked differences above grepcent's stated thresholds were found between the earliest XBRL-filed value and the value currently on file for the same fiscal period.

Ledger: /company/NUTX/revisions/


## Quarterly

Quarterly standardized facts from SEC companyfacts as of latest extracted filing date 2026-08-06. Source: https://data.sec.gov/api/xbrl/companyfacts/CIK0001479681.json.

Flow metrics use discrete quarter-length periods from 10-Q/10-Q/A filings. Q4 revenue and net income are derived only when annual FY and nine-month YTD facts exist for the same fiscal year; derived Q4 values are labeled. EPS Q4 is not derived.

| Quarter | End date | Revenue | Net income | Diluted EPS | Method |
| --- | --- | ---: | ---: | ---: | --- |
| 2022-Q3 | 2022-09-30 |  |  | -0.65 | reported discrete quarter |
| 2023-Q1 | 2023-03-31 |  |  | -0.01 | reported discrete quarter |
| 2023-Q2 | 2023-06-30 |  |  | -0.01 | reported discrete quarter |
| 2023-Q3 | 2023-09-30 | 62,722,972 | -5,542,391 | -0.01 | reported discrete quarter |
| 2023-Q4 | 2023-12-31 | 69,669,473 | -31,617,897 |  | derived Q4 = FY annual - nine-month YTD |
| 2024-Q1 | 2024-03-31 | 67,453,787 | -364,075 | -0.01 | reported discrete quarter |
| 2024-Q2 | 2024-06-30 | 76,082,261 | -364,048 | -0.07 | reported discrete quarter |
| 2024-Q3 | 2024-09-30 | 78,794,869 | -8,788,313 | -1.72 | reported discrete quarter |
| 2024-Q4 | 2024-12-31 | 257,617,716 | 61,695,604 |  | derived Q4 = FY annual - nine-month YTD |
| 2025-Q1 | 2025-03-31 | 211,789,000 | 14,634,000 | 2.56 | reported discrete quarter |
| 2025-Q2 | 2025-06-30 | 243,985,000 | -17,697,000 | -2.95 | reported discrete quarter |
| 2025-Q3 | 2025-09-30 | 267,804,000 | 55,435,000 | 7.76 | reported discrete quarter |
| 2025-Q4 | 2025-12-31 | 151,679,000 | 11,834,000 |  | derived Q4 = FY annual - nine-month YTD |
| 2026-Q1 | 2026-03-31 | 216,485,000 | 46,807,000 | 6.52 | reported discrete quarter |
| 2026-Q2 | 2026-06-30 | 210,752,000 | 65,842,000 | 9.38 | reported discrete quarter |

## Filed narrative (10-K & 10-Q)

## Business

Verbatim Item 1 Business section from NUTX's latest 10-K: [/company/NUTX/business/](/company/NUTX/business/).

## Risk Factors

Verbatim Item 1A Risk Factors from NUTX's latest 10-K: [/company/NUTX/risk-factors/](/company/NUTX/risk-factors/).

## Latest quarter (10-Q)

Latest 10-Q source: https://www.sec.gov/Archives/edgar/data/1479681/000162828026054268/nutx-20260630.htm

Extracted structurally from real Item 2 body heading to real Item 3/4 boundary. Published MD&A gate trimmed front/tail over-capture.
Confidence: high
Filing date: 2026-08-06
Report date: 2026-06-30

Item 2 – Management’s Discussion and Analysis of Financial Condition and Results of Operations

The following Management’s Discussion and Analysis of Financial Condition and Results of Operations should be read in conjunction with the unaudited condensed consolidated financial statements and the notes thereto included in Part I, Item 1, “Financial Statements” of this Quarterly Report on Form 10-Q.

Overview

Nutex Health Inc. is a physician-led, healthcare services and operations company with 27 hospital facilities in 12 states (hospital division), and a primary care-centric, risk-bearing population health management division. Our hospital division implements and operates innovative health care models, including micro-hospitals, specialty hospitals and hospital outpatient departments. The population health management division owns and operates provider networks such as independent physician associations (“IPAs”).

As of June 30, 2026, we employed approximately 1,037 full-time employees, contracted with over 280 doctors at our facilities and partnered with over 3,600 physicians within our networks. Our corporate headquarters is based in Houston, Texas. We were incorporated on April 13, 2000 in the state of Delaware.

Our financial statements present the Company’s unaudited condensed consolidated financial condition and results of operations including those of majority-owned subsidiaries and variable interest entities (“VIEs”) for which we are the primary beneficiary.

The hospital division includes our hospital entities. In addition, we have financial and operating relationships with multiple professional entities (the “Physician LLCs”) and real estate entities part of the real estate division. The Physician LLCs employ the doctors who work in our hospitals. These entities are consolidated by the Company as VIEs because they do not have significant equity at risk to finance their activities independently. The Company is considered the primary beneficiary of these entities because (i) it has the power to direct the activities that most significantly affect their economic performance through its contractual and operational oversight, and (ii) it has the obligation to absorb losses and the right to receive benefits that could be significant, as evidenced by the Company’s historical practice of providing financial support during periods of cash shortfall and receiving the benefit of services. While the Company does not hold any direct equity or indirect ownership interest in the Physician LLCs, it is deemed to have an indirect economic interest through its contractual relationships with intermediary entities. Certain of the Physician LLCs are owned in part and, in some cases, controlled by related parties, including members of the Company’s executive management team.

The real estate division comprises of real estate entities along with activity related to the development and construction of hospital facilities. The real estate entities own the land and hospital buildings which are leased to our hospital entities. The real estate entities also include the Company's headquarters. These entities have mortgage loans payable to third parties which are collateralized by the land and buildings. We consolidate certain real estate entities as VIEs (the "Real Estate VIEs") in instances where our hospital entities are guarantors or co-borrowers under their outstanding mortgage loans. As of June 30, 2026, we continue to consolidate two Real Estate VIEs in our financial statements. The Real Estate VIEs are in part and, in some cases, controlled by related parties, including members of the Company’s executive management team.

The population health management division includes our management services organization. Additionally, Atlas Healthcare Physicians ("Atlas", formerly known as "Associated Hispanic Physicians of So. California"), a physician-affiliated entity that is not owned by us, is consolidated as a VIE of our wholly-owned subsidiary AHP since we are the primary beneficiary of their operations under AHP’s management services contracts with them.

Sources of revenue. Our hospital division recognizes net patient service revenue for contracts with patients and in most cases a third-party payor (commercial insurance, workers compensation insurance or, in limited cases, Medicare/Medicaid).

We receive payment for facility services rendered by us from federal agencies, private insurance carriers and patients. The Physician LLCs receive payment for doctor services from these same sources. On average, greater than 99% of our net patient service revenue is paid by insurers, federal agencies and other non-patient third parties. The remaining revenues are paid by our patients in the form of copays, deductibles and self-payment. We generally operate as an out-of-network provider and as such, do not have negotiated reimbursement rates with insurance companies.

26

Table of Contents

The following tables present the allocation of the transaction price with the patient between the primary patient classification of insurance coverage:

[[GREPCENT_TABLE]]
[["","","Three Months Ended June 30,","","Six Months Ended June 30,"],["","","2026","","2025","","2026","","2025"],["Insurance","","96","%","","97","%","","97","%","","96","%"],["Self-pay","","2","%","","1","%","","1","%","","2","%"],["Workers' compensation","","1","%","","1","%","","1","%","","1","%"],["Medicare/Medicaid","","1","%","","1","%","","1","%","","1","%"],["Total","","100","%","","100","%","","100","%","","100","%"]]
[[/GREPCENT_TABLE]]

Arbitration process

Federal Rules Applicable to Out-of-Network Billing

Congress enacted the No Surprises Act effective January 1, 2022, to protect patients from surprise medical bills incurred when they receive emergency medical services from out-of-network healthcare providers, as well as non-emergency services at in-network facilities, and air ambulance services. The NSA achieves this by relieving patients from financial liability for surprise bills and creating an independent dispute resolution process for billing disputes between providers and insurers. The patient is not involved in this process, and payment is issued directly to the provider. The IDR process safeguards providers by promoting fair reimbursement from payors, helping ensure their continued ability to deliver care.

•Independent Dispute Resolution. Under the IDR provisions, Nutex Health and the insurer first must try to agree on a price for the services. If negotiations fail, either party has four days to initiate IDR proceedings. If the parties pursue IDR, either the parties or the Department of Health and Human Services selects a certified independent dispute resolution entity or CIDRE to determine the final payment amount.

•Certified Independent Dispute Resolution Entity. The CIDRE has the sole discretion to determine both the eligibility of claims submitted for the IDR process, subject to federal and state regulations, and the amount the payor owes the provider.

•The CIDRE makes a threshold determination of IDR eligibility and sets the payment amount by choosing between the offers of each party; the provider and insurer each submit a final offer, and the CIDRE selects one party’s offer as the award after reviewing and evaluating all statutorily required information submitted by both parties.

•In deciding which offer to award, the CIDRE must consider several factors outlined in the law, only one of which is the qualifying payment amount (“QPA”), which is calculated by the insurer, subject to the statutory definition as the “median of the contracted rates recognized by the plan or issuer . . . for the same or a similar item or service” offered in the same insurance market and geographic area. The QPA calculation is made in accordance with the 2021 methodology, which is subject to pending court challenges. See Legal challenges to HHS Final Rule below. Among the other factors to be considered by the CIDRE are the complexity or acuity of the case, the doctor’s expertise, and the scope of services provided at the facility.

•Arbitration Awards Are Binding. In the absence of a fraudulent claim or evidence of a misrepresentation of facts to the CIDRE, the IDR award is binding upon the parties involved and payment of the award must be made not later than 30 days after the date on which the payment determination is made.

•Patients are not involved in open negotiations or the IDR process, and payors must issue any IDR award payments directly to the provider.

•The NSA empowers HHS to assess penalties against insurers for failure to comply with the NSA, including timely payment of CIDRE awards. However, significant enforcement gaps remain in the current law. For example, during 2025, the United States Courts of Appeals for the Fifth and Eleventh Circuits held that providers do not have a private right of action to enforce IDR awards under the NSA and that enforcement authority rests exclusively with HHS. Some courts in other circuits have disagreed. In January 2026, the United States Supreme Court declined review of this issue.

27

Table of Contents

•Highlighting the complexity and uncertainty with the NSA and IDR process and the unsuccessful results by various insurers, there are numerous pending lawsuits brought by insurers against IDR vendors and providers (other than Nutex), challenging the awards made in favor of the IDR vendors (including Nutex's vendor, HaloMD) and providers. The insurers have alleged, among other things, that the defendant vendors and providers engaged in fraudulent schemes with respect to IDR eligibility determinations. During 2026, federal district courts in several jurisdictions have granted the defendants’ motions to dismiss many of these lawsuits, primarily on the grounds that the NSA bars judicial review of IDR determinations except for certain narrow exceptions permitted under the Federal Arbitration Act that were not met. In one of these dismissed cases that had been filed against HaloMD in the Northern District of Georgia, the court further held that the insurer had not adequately alleged a plausible fraud claim, reasoning that it was “highly improbable to infer from these facts that there is a vast conspiracy of providers and IDREs that have conspired to defraud the [insurer] of millions of dollars in thousands of NSA IDR proceedings,” and that it was “highly plausible to infer that the [insurer] engages in a consistent practice of submitting lowball offers to out-of-network providers in an effort to maximize its profits.” However, many other lawsuits remain pending, and the dismissal rulings are subject to appeal.

•Reopening of Disputes Closed Prior to June 6, 2025 Only for CIDRE Clerical, Jurisdictional or Procedural Errors. On June 6, 2025 HHS published a Technical Assistance allowing the reopening of disputes (1) received on or after June 6, 2025, or (2) received prior to June 5, 2025, but not responded to prior to June 6, 2025. Reopening is permitted solely for clerical, jurisdictional or procedural errors by the CIDRE. Errors by the parties or substantive disputes among the parties, in particular, with respect to the qualifying payment amount and related statutorily prescribed factors, will not result in a reopening. In addition, HHS has increased the number of CIDREs from 13 to 16 and updated the federal submission portal with respect to, among other things, service-code modifier fields, duplicate-dispute validation, and resubmission rules.

•Federal IDR Operations Final Rule. On May 28, 2026, CMS and federal agencies published the Federal Independent Dispute Resolution Operations final rule, significantly restructuring the Federal IDR Process. Key changes include:

•the non-refundable administrative fee was reduced from $115 to $15 per party per dispute for disputes initiated on or after June 11, 2026;

•for batched disputes only, the cooling off period was reduced from 90 days to 30 d

[Excerpt truncated for page length; source filing is linked above.]

## Latest 10-K MD&A (excerpt)

Latest 10-K Item 7 source: https://www.sec.gov/Archives/edgar/data/1479681/000162828026015168/nutx-20251231.htm
Complete FY 2025 MD&A: /company/NUTX/mda/fy2025/

Extracted structurally from real Item 7 body heading to real Item 7A/8 boundary.
Confidence: high
Filing date: 2026-03-05
Report date: 2025-12-31

Item 7. Management’s Discussion and Analysis of Financial Condition and Results of Operations

The following discussion is intended to assist you in understanding our results of operations and our present financial condition and contains forward-looking statements that reflect our future plans, estimates, beliefs and expected performance. The forward-looking statements are dependent upon events, risks and uncertainties that may be outside our control. We caution you that our actual results could differ materially from those discussed in these forward-looking statements. Factors that could cause or contribute to such differences are discussed elsewhere in this Annual Report, particularly in the “Cautionary Note Regarding Forward-Looking Statements” and “Risk Factors,” all of which are difficult to predict. In light of these risks, uncertainties and assumptions, the forward-looking events discussed may not occur. We do not undertake any obligation to publicly update any forward-looking statements except as otherwise required by applicable law.

Overview

Nutex Health Inc. is a physician-led, healthcare services and operations company with 26 hospital facilities in 12 states (hospital division), and a primary care-centric, risk-bearing population health management division. Our hospital division implements and operates innovative health care models, including micro-hospitals, specialty hospitals and hospital outpatient departments (“HOPDs”). The population health management division owns and operates provider networks such as independent physician associations (“IPAs”) and offers a cloud-based proprietary technology platform to IPAs which aggregates clinical and claims data across multiple settings, information systems and sources to create a holistic view of patients and providers.

At December 31, 2025, we employed approximately 944 full-time employees, contracted more than 280 doctors at our facilities and partnered with over 3,600 physicians within our networks. Our corporate headquarters is based in Houston, Texas. We were incorporated on April 13, 2000 in the state of Delaware.

41

Table of Contents

Our financial statements present the Company’s consolidated financial condition and results of operations including those of majority-owned subsidiaries and variable interest entities (“VIEs”) for which we are the primary beneficiary.

The hospital division includes our healthcare billing and collections organization and hospital entities. In addition, we have financial and operating relationships with multiple professional entities (the “Physician LLCs”) and real estate entities (the “Real Estate Entities”). The Physician LLCs employ the doctors who work in our hospitals. These Physician LLCs are consolidated by the Company as VIEs because they do not have sufficient equity at risk to finance their activities independently. The Company is considered the primary beneficiary of these entities because (i) it has the power to direct the activities that most significantly affect their economic performance through its contractual and operational oversight, and (ii) it has the obligation to absorb losses and the right to receive benefits that could be significant, as evidenced by the Company’s historical practice of providing financial support during periods of cash shortfall and receiving the benefit of services.

The Real Estate Entities own the land and hospital buildings which are leased to our hospital entities. The Real Estate Entities have mortgage loans payable to third parties which are collateralized by the land and buildings. We consolidate the Real Estate Entities as VIEs in instances where our hospital entities are guarantors or co-borrowers under their outstanding mortgage loans. As of December 31, 2025, two Real Estate Entities continue to be consolidated in our financial statements as VIEs.

The Company has no direct or indirect ownership interest in the Physician LLCs. The Company has no direct or indirect interests in the Real Estate Entities except for the two noted above and a 51% ownership in the May 2025 Acquiree (see Note 3 - Mergers, Acquisitions and Divestitures), so 100% of the equity for these entities is shown as noncontrolling interest in the consolidated balance sheets and statements of operations.

The population health management division includes our management services organizations. In addition, Atlas Healthcare Physicians (“Atlas”, formerly known as “Associated Hispanic Physicians of So. California”), a physician-affiliated entity that is not owned by us—is consolidated as a VIE of our wholly-owned subsidiary AHP since we are the primary beneficiary of their operations under AHP’s management services contracts with them.

Sources of revenue. Our hospital division recognizes net patient service revenue for contracts with patients and in most cases a third-party payor (commercial insurance, workers compensation insurance or, in limited cases, Medicare/Medicaid).

We receive payment for facility services rendered by us from federal agencies, private insurance carriers, and patients. The Physician LLCs receive payment for doctor services from these same sources. On average, greater than 99% of our net patient service revenue is paid by insurers, federal agencies, and other non-patient third parties. The remaining revenues are paid by our patients in the form of copays, deductibles, and self-payment. We generally operate as an out-of-network provider and, as such, do not have negotiated reimbursement rates with insurance companies.

The following tables present the allocation of the transaction price with the patient between the primary patient classification of insurance coverage:

[[GREPCENT_TABLE]]
[["","","Year Ended December 31,"],["","","2025","","2024","","2023"],["Insurance","","97","%","","94","%","","93","%"],["Self pay","","1","%","","3","%","","4","%"],["Workers compensation","","1","%","","2","%","","2","%"],["Medicare/Medicaid","","1","%","","1","%","","1","%"],["Total","","100","%","","100","%","","100","%"]]
[[/GREPCENT_TABLE]]

The population health management division recognizes revenue for capitation and management fees for services to IPAs monthly. Capitation revenue consists primarily of capitated fees for medical services provided by physician-owned entities we consolidate as VIEs. Capitated arrangements are made directly with various managed care providers including HMOs. Capitation revenues are typically paid to us monthly in the period services are provided based on the number of enrollees selecting us as their healthcare provider. Capitation is a fixed payment amount per patient per unit of time paid in advance

42

Table of Contents

for the delivery of health care services, whereby the service providers are generally liable for excess medical costs. We receive management fees that are based on gross capitation revenues of the IPAs or physician groups we manage.

Our growth strategy. We plan to expand our operations by expanding our clinical services at our existing facilities, by entering new market areas either through development of new hospitals, formation of new IPAs or by making acquisitions. We expect to open three new hospital facilities by the end of 2026. These facilities are either under construction or in advanced planning stages. We anticipate launching one-to-three additional IPAs per year, principally in geographic areas around our existing micro-hospitals.

Industry Trends

The demand for healthcare services continues to be impacted by the following trends:

•Regulatory uncertainty;

•A growing focus on healthcare spending by consumers, employers and insurers, who are actively seeking lower-cost care solutions;

•A shift in patient volumes from inpatient to outpatient settings due to technological advancements and demand for care that is more convenient, affordable and accessible;

•The growing aged population, which requires greater chronic disease management and higher-acuity treatment; and

•Ongoing consolidation of providers and insurers across the healthcare industry.

The healthcare industry, particularly emergency care hospitals, continues to be subject to ongoing regulatory uncertainty. Changes in federal or state healthcare laws, regulations, funding policies or reimbursement practices, especially those involving reductions to government payment rates or limitations on what providers may charge, could significantly impact future revenue and operations. For example, the No Surprises Act prohibits providers from charging patients an amount beyond the in-network cost sharing amount for services rendered by out-of-network providers, subject to limited exceptions. For services for which balance billing is prohibited, the No Surprises Act includes provisions that may limit the amounts received by out-of-network providers from health plans. Any reduction in the rates that we can charge or amounts we can receive for our services will reduce our total revenue and our operating margins.

Results of Operations

We report the results of our operations as three segments in our consolidated financial statements: (i) the hospital division, (ii) the population health management division and (iii) the real estate division. Activity within our business segments is significantly impacted by the demand for healthcare services we provide, competition for these services in each of the market areas we serve, and the legislative changes discussed above.

43

Table of Contents

Following is our results of operations for the periods shown (in thousands):

[[GREPCENT_TABLE]]
[["","Year ended December 31,"],["","2025","","2024","","2023"],["Revenue:"],["Hospital division","$","844,162","","","$","449,064","","","$","218,070"],["Population health management division","31,095","","","30,885","","","29,576"],["Total revenue","875,257","","","479,949","","","247,646"],["Segment operating income (loss):"],["Hospital division","444,027","","","195,539","","","36,336"],["Population health management division","690","","","1,380","","","(1,559)"],["Real estate division","(436)","","","(658)","","","(3)"],["Total segment operating income","444,281","","","196,261","","","34,774"],["Corporate and other costs:"],["Facilities closing costs","\u2014","","","\u2014","","","217"],["Acquisition costs","\u2014","","","\u2014","","","44"],["Stock-based compensation","117,003","","","16,555","","","2,836"],["Impairment of assets","\u2014","","","3,887","","","29,082"],["Impairment of goodwill","\u2014","","","3,197","","","1,139"],["General and administrative expenses","51,653","","","41,924","","","33,230"],["Total corporate and other costs","168,656","","","65,563","","","66,548"],["Interest expense","22,226","","","19,932","","","16,318"],["Loss on warrant liability","\u2014","","","1,609","","","\u2014"],["Other expense (income)","8,618","","","(669)","","","399"],["Income (loss) before taxes","244,781","","","109,826","","","(48,491)"],["Income tax expense (benefit)","64,424","","","15,020","","","(5,067)"],["Net income (loss)","180,357","","","94,806","","","(43,424)"],["Less: net income attributable to noncontrolling interests","109,568","","","42,709","","","2,363"],["Net income (loss) attributable to Nutex Health Inc.","$","70,789","","","$","52,097","","","$","(45,787)"],["Adjusted EBITDA","$","259,565","","","$","102,774","","","$","(5,830)"]]
[[/GREPCENT_TABLE]]

Year Ended December 31, 2025 Compared to Year Ended December 31, 2024

We reported net income attributable to Nutex Health Inc. of $70.8 million, or earnings of $10.48 per share, for 2025 as compared with a net income attributable to Nutex Health Inc. of $52.1 million, or earnings of $9.69 per share, for 2024. Our 2025 results were principally affected by:

•Patient visits rose by 11.8% for the year ended December 31, 2025, compared to the same period in 2024. Mature hospitals experienced an average visit growth of 1.3% year-over-year, alongside the impact of two new ho

[Excerpt truncated for page length; the complete text is on the linked full-MD&A page.]

Read the full FY 2025 MD&A: /company/NUTX/mda/fy2025/
All MD&A years: /company/NUTX/mda/


## MD&A history

Prior-year 10-K MD&A spans are extracted from SEC filings with the same bounded parser used for the latest filing. Each year's full verbatim text is on its own sub-page.

- [FY 2024 MD&A](/company/NUTX/mda/fy2024/): filed 2025-03-31; accession 0001479681-25-000006 (https://www.sec.gov/Archives/edgar/data/1479681/000147968125000006/nutx-20241231x10k.htm)
- [FY 2023 MD&A](/company/NUTX/mda/fy2023/): filed 2024-03-29; accession 0001558370-24-004287 (https://www.sec.gov/Archives/edgar/data/1479681/000155837024004287/nutx-20231231x10k.htm)
- [FY 2022 MD&A](/company/NUTX/mda/fy2022/): filed 2023-03-03; accession 0001558370-23-002713 (https://www.sec.gov/Archives/edgar/data/1479681/000155837023002713/nutx-20221231x10k.htm)
- [FY 2021 MD&A](/company/NUTX/mda/fy2021/): filed 2022-03-31; accession 0001607062-22-000229 (https://www.sec.gov/Archives/edgar/data/1479681/000160706222000229/clnh123121form10k.htm)




## Macro cross-references

Indicators mapped to this company's SIC classification (industry 7389 Services-Business Services, NEC) by grepcent's deterministic macro-sector crosswalk. A navigational mapping, not a statistical or causal claim.

- [PAYEMS](/indicator/PAYEMS/): All Employees, Total Nonfarm
- [CES0500000003](/indicator/CES0500000003/): Average Hourly Earnings of All Employees, Total Private
- [DGS10](/indicator/DGS10/): Market Yield on U.S. Treasury Securities at 10-Year Constant Maturity

Macro-to-micro threads including this sector: [US labor market](/thread/us-labor-market/), [Growth & output](/thread/growth-output/), [Government finances](/thread/government-finances/), [Sector employment](/thread/sector-employment/).

All macro indicators: /indicators/


## For LLMs & downloads

Markdown twin: /company/NUTX.md · JSON record: /company/NUTX.json · verified financials: /company/NUTX/financials.json / /company/NUTX/financials.csv · machine TOC for the whole site: /llms.txt